Merck & Co., Inc.
Merck is a global health care company that provides prescription medicines, biologic therapies, vaccines and animal health products. Its two reportable segments are Pharmaceutical and Animal Health. Pharmaceutical includes human medicines, generally sold by prescription to treat or prevent disorders, and preventive vaccines for children, adolescents and adults. Merck sells these products primarily to wholesalers, retailers, hospitals, government agencies, health care providers, physicians and distributors. Animal Health discovers, develops, manufactures and markets veterinary medicines and vaccines, health management solutions and services, and digitally connected products for animal identification, traceability and monitoring. Its customers include veterinarians, distributors, animal producers, farmers and pet owners. Merck’s products serve livestock and companion animals, with brands including Keytruda, Gardasil, Januvia, Bravecto and Nobivac. It earns money from product sales and alliance revenue, including its share of profits from certain collaborative products. Merck is headquartered in Rahway, New Jersey.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $MRK in the last 30 days.
See all $MRK insider activity →Merck KGaA (MRK.DE) agreed to sell its CDMO business to Lonza, with the deal expected to close in 2027. Toyota (7203.T) and Waymo will collaborate to install Waymo's AV hardware in Toyota's bZ4X SUVs, starting in 2027. BASF (BAS.DE) plans to invest in a new semiconductor materials facility in China, with production beginning in 2028. Fragment, a private company, raised $56M to develop its ACE platform.
Merck (MRK) stock has traded above its 200-day SMA for over a year and above its 50-day SMA since Nov. 4, 2026, indicating strong investor confidence. Keytruda, accounting for 55% of pharmaceutical sales, drove $23.6B in sales in 2026's first nine months. Merck's pipeline and acquisitions aim to offset Keytruda's 2028 patent expiration and Gardasil's declining sales.
Moderna and Merck are advancing their personalized melanoma therapy, intismeran, toward regulatory approval. Moderna's Q3 earnings show a 90% revenue drop from 2022 to 2025 due to reduced COVID-19 vaccine demand. The Phase 3 trial showed a 42% reduction in recurrence or death risk when combined with Keytruda. Moderna shares have risen over 700% this year, driven by investor excitement over the cancer program.
Over the past 7 days, AlphAI's AI scored 52 news stories mentioning MRK (Merck & Co., Inc.). Coverage has skewed bullish: 23 bullish, 20 neutral, and 9 bearish.
Recent MRK coverage spans financial news and mergers & acquisitions.
Merck KGaA (MRK.DE) agreed to sell its CDMO business to Lonza, with the deal expected to close in 2027. Toyota (7203.T) and Waymo will collaborate to install Waymo's AV hardware in Toyota's bZ4X SUVs, starting in 2027. BASF (BAS.DE) plans to invest in a new semiconductor materials facility in China, with production beginning in 2028. Fragment, a private company, raised $56M to develop its ACE platform.
No fresh catalyst; existing momentum may continue modestly.
Merck shares may see modest upside from the positive trial, reflecting its stake in the partnership.
Emergency authorization is a positive regulatory step that can accelerate uptake and generate incremental revenue, albeit likely limited by scale.
Neutral to modestly positive as Merck gains a dedicated digital distribution partner in a large market.
AlphAI scores every news story that mentions MRK with an AI model for sentiment and relevance, and aggregates insider trades from Merck & Co., Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Merck KGaA (MRK.DE) agreed to sell its CDMO business to Lonza, with the deal expected to close in 2027. Toyota (7203.T) and Waymo will collaborate to install Waymo's AV hardware in Toyota's bZ4X SUVs, starting in 2027. BASF (BAS.DE) plans to invest in a new semiconductor materials facility in China, with production beginning in 2028. Fragment, a private company, raised $56M to develop its ACE platform.
Merck (MRK) stock has traded above its 200-day SMA for over a year and above its 50-day SMA since Nov. 4, 2026, indicating strong investor confidence. Keytruda, accounting for 55% of pharmaceutical sales, drove $23.6B in sales in 2026's first nine months. Merck's pipeline and acquisitions aim to offset Keytruda's 2028 patent expiration and Gardasil's declining sales.
Moderna and Merck are advancing their personalized melanoma therapy, intismeran, toward regulatory approval. Moderna's Q3 earnings show a 90% revenue drop from 2022 to 2025 due to reduced COVID-19 vaccine demand. The Phase 3 trial showed a 42% reduction in recurrence or death risk when combined with Keytruda. Moderna shares have risen over 700% this year, driven by investor excitement over the cancer program.
AstraZeneca offered $10B for Rhythm Pharmaceuticals. Boehringer Ingelheim licensed 6 cancer drugs from Sino Biopharmaceutical for $358M upfront. AbbVie licensed Nxera Pharma’s program for $100M. Lonza acquired 5 CDMO sites from Merck KGaA. Teva and Samsung Bioepis licensed 2 biosimilars. FDA approved Inovio’s Voceryq, sending shares up 257%. Agios, UniQure, NRx Pharma had FDA updates. Formation Bio raised $600M. Molecular Partners, Lenz Therapeutics, Ultragenyx announced layoffs.
JD Health and Merck Healthcare signed a 3-year agreement for JD Health to prioritize new drug launches. JD Health also announced partnerships with 20+ global brands. JD Health has launched over 100 new drugs in 2026, including Novartis, Pfizer, and Takeda products. Merck aims to expand patient coverage through digital platforms. JD Health is China's largest pharmaceutical retail platform by revenue.
Lonza, a Swiss contract manufacturing firm, will acquire five US sites from Merck KGaA. The deal, valued in the low- to mid-triple-digit million Swiss francs, will expand Lonza's US manufacturing network. Details on the sites, products, and financing remain undisclosed.
Merck has initiated a Phase 3 trial (ENHANCE-3) for ensifentrine (Ohtuvayre), evaluating its efficacy in reducing COPD exacerbations. The global study will enroll 2,136 patients across 28 countries. Ohtuvayre, approved by the FDA in June 2024, is a dual-action inhaled therapy for COPD maintenance.
Merck reported that its dual GLP-1/glucagon agonist drug cleared a mid-stage trial for liver disease MASH, sharing biopsy data. The drug was licensed from South Korea's Hanmi.
Merck faces a 57% revenue drop for Keytruda by 2032 due to patent expirations. GlobalData forecasts non-oncology portfolio growth to double in six years, offsetting the decline. This diversification is expected to drive overall revenue growth, according to the report.
State Street Health Care Select Sector SPDR ETF (XLV) bought $330.3M in stocks on Nov. 3, increasing all 60 holdings. Top purchases included Eli Lilly (LLY) at $56.0M, Johnson & Johnson (JNJ) at $31.8M, and AbbVie (ABBV) at $25.1M. XLV has $49.13B in assets and a 0.08% expense ratio.
